Androgen-deprivation therapy (ADT) is standard treatment for locally advanced or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration-resistant PCa [CRPC]) after approximately 2-3 yr, with a poor prognosis. The molecular mechanisms underlying CRPC progression are unclear.To undertake quantitative tumour transcriptome profiling prior to and following ADT to identify functionally important androgen-regulated pathways or genes that may be reactivated in CRPC....Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
articletitle: Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
journaltitle: European Urology
copyright: Copyright © 2013 European Association of Urology. Published by Elsevier B.V.